Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors

A Toll-like receptor recognizes bacterial DNA

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works

CpG Motifs in Bacterial DNA and Their Immune Effects

Krieg, A. Μ. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,570 · see citing works

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · see citing works

Clinical translation of angiogenesis inhibitors

Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,513 · see citing works

Prognostic Factors in Prostate Cancer

Bostwick, D. G., Grignon, D. J., Hammond, M. E., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montironi, R., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0995-pfipc · Cited by 1,365 · see citing works

Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257 · see citing works

Prognostic Factors in Colorectal Cancer

Compton, C. C., FIELDING, L. P., Burgart, L. J., Conley, B. A., Cooper, H. S., Hamilton, S. R., Hammond, M. E. H., Henson, D. E., Hutter, R. V. P., Nagle, R. B., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0979-pficc · Cited by 1,251 · see citing works

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria‐Petit, A., Crombet, T., Jothy, S., Hicklin, D. J., Böhlen, P., Schlaeppi, J.-M., Rak, J. W., & Kerbel, R. S. (2001) · PubMed · Cited by 558 · see citing works

Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., & Fidler, I. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204535 · Cited by 556 · see citing works

Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment

Grünwald, V., & Hidalgo, M. M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383 · see citing works

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 379 · see citing works

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347 · see citing works

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

Fan, Z., Masui, H., Altas, I., & Mendelsohn, J. M. (1993) · PubMed · Cited by 245 · see citing works

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

Ciardiello, F., & Tortora, G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00235-1 · Cited by 245 · see citing works

Synthetic Oligonucleotides with Particular Base Sequences from the cDNA Encoding Proteins of Mycobacterium bovis BCG Induce Interferons and Activate Natural Killer Cells

Tokunaga, T., Yano, O., Kuramoto, E., et al. (1992) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1992.tb01642.x · Cited by 179 · see citing works

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity

Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P. W., Fisher, D. C., Nadler, L. M., Coffman, R. L., & Freedman, A. S. (2004) · Blood · doi:10.1182/blood-2004-06-2156 · Cited by 151 · see citing works

CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation

Milas, L., Mason, K. A., Ariga, H., Hunter, N. R., Neal, R. E., Valdecanas, D. R., Krieg, A. Μ., & Whisnant, J. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0926 · Cited by 151 · see citing works

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

Ciardiello, F., Damiano, V., Bianco, R., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.23.1770 · Cited by 138 · see citing works

How BCG Led to the Discovery of Immunostimulatory DNA

Tokunaga, T., Yamamoto, T., & Yamamoto, S. (1999) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.52.1 · Cited by 130 · see citing works

The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-κB (NF-κB)-inducing Kinase to Activate NF-κB

Habib, A. A., Chatterjee, S., Park, S.-K., Ratan, R. R., Lefebvre, S., & Vartanian, T. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008458200 · Cited by 130 · see citing works

Oncogenic and Anti-apoptotic Activity of NF-κB in Human Thyroid Carcinomas

Pacifico, F., Mauro, C., Barone, C., Crescenzi, E., Mellone, S., Monaco, M., Chiappetta, G., Terrazzano, G., Liguoro, D., Vito, P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403492200 · Cited by 102 · see citing works

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists

Kandimalla, E. R., Bhagat, L., Li, Y., Yu, D. S., Wang, D., Cong, Y., Song, S. S., Tang, J. X., Sullivan, T., & Agrawal, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501729102 · Cited by 98 · see citing works

DNA containing CpG motifs induces angiogenesis

Zheng, M., Klinman, D. M., Gieryńska, M. M., & Rouse, B. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132605599 · Cited by 95 · see citing works

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik, H. H., Bevaart, L., Dahle, C. E., Bakker, A., Jansen, M., van Vugt, M. J., van de Winkel, J. G. J., & Weiner, G. J. (2003) · PubMed · Cited by 93 · see citing works

'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents

Yu, D. S. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf582 · Cited by 80 · see citing works

Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients

Blazar, B. R., Krieg, A. Μ., & Taylor, P. A. (2001) · Blood · doi:10.1182/blood.v98.4.1217 · Cited by 79 · see citing works

Antisense c-myc and Immunostimulatory Oligonucleotide Inhibition of Tumorigenesis in a Murine B-Cell Lymphoma Transplant Model

Smith, J. B., & Wickstrom, E. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1146 · Cited by 76 · see citing works

Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles

Kandimalla, E. R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg343 · Cited by 65 · see citing works

Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts

Balsari, A., Tortoreto, M., Besusso, D., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.023 · Cited by 56 · see citing works

Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of Mycobacterium bovis BCG

Kataoka, T., Yamamoto, S., Yamamoto, T., et al. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb00094.x · Cited by 45 · see citing works

Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs

Kandimalla, E. R., Zhu, F., Bhagat, L., et al. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310654 · Cited by 39 · see citing works

Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs

Wang, D., Li, Y., Yu, D., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.4.901 · Cited by 34 · see citing works

Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNA

Sfondrini, L., Besusso, D., Rumio, C., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0383com · Cited by 31 · see citing works

Towards optimal design of second-generation immunomodulatory oligonucleotides.

Kandimalla, E. R., Yu, D. S., & Agrawal, S. (2002) · PubMed · Cited by 29 · see citing works

Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells.

Ciardiello, F., Bianco, R., Damiano, et al. (2000) · Cited by 4 · see citing works

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160 · see citing works

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i> - <i>Ras</i> Mutant Colorectal and Pancreatic Cancers

Rosa, R., Melisi, D., Damiano, V., Bianco, R., Garofalo, S., Gelardi, T., Agrawal, S., Di Nicolantonio, F., Scarpa, A., Bardelli, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3376 · Cited by 54 · see citing works

Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer

문대성, 장태원, Ok, C. H., 정만홍, 김도현, & 최인수 (2009) · The Korean Journal of Internal Medicine

Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.

Shao, Y., Lin, C., & Yang, C.-H. (2010) · PubMed · Cited by 13 · see citing works

Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity

Kunimasa, K., Yoshioka, H., Iwasaku, M., Nishiyama, A., Korogi, Y., Masuda, G., Takaiwa, T., & Ishida, T. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6285 · Cited by 26 · see citing works

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment

Сонг, Zheng-bo, Yu, et al. (2011) · 中华医学杂志：英文版

Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.

Yonesaka, K., Suzumura, T., Tsukuda, H., Hasegawa, Y., Ozaki, T., Sugiura, T., & Fukuoka, M. (2014) · PubMed · Cited by 13 · see citing works